Delivery Order SPE2DB22D2218-SPE2DB24FR2GH
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $2,967.56 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the delivery of ENGERIX-B 20 MCG/ML SYRNML, a hepatitis B vaccine, to support military treatment programs and facilities. This delivery order contract is part of a larger indefinite delivery contract (IDC) awarded...
- The U.S. Defense Logistics Agency (DLA) has awarded a Firm Fixed Price Delivery Order contract to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The contract, valued at $8,996.48, is for the supply of HYPERRAB 300 UNIT/ML VIAL 3ML, a medical product. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 held by Amerisourcebergen with DLA Troop Support Medical, which serves as the primary vehicle for...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $78,864.00 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to deliver...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $11,270.10 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the supply of 4566039591 HYPERRAB 300 UNIT/ML VIAL 5ML, with a period of performance through October 29, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 between DLA Troop Support Medical and Amerisourcebergen, which provides a...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The $7,513.40 award is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a specialty pharmaceutical product. This delivery order is issued under an Indefinite Delivery Contract (IDC) awarded solely to AmerisourceBergen Drug Corp, with a potential value of up to...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $18,783.50 to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product, with a completion date of July 24, 2024. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as the primary...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The $1,577.28 award has a completion date of February 13, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00, that serves as the primary vehicle for the company to deliver pharmaceutical products...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a Firm Fixed Price delivery order contract valued at $1,116.57 by the Defense Logistics Agency (DLA) to provide HYPERRAB 300 UNIT/ML VIALML pharmaceuticals. This delivery order is part of a larger Indefinite Delivery Contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary...
- The Defense Logistics Agency (DLA) awarded a Delivery Order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HYPERRAB 300 UNIT/ML VIALML pharmaceutical products. The $3,721.90 Firm Fixed Price contract has an ultimate completion date of May 17, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, to deliver a comprehensive range of...
- This is a delivery order contract awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA), a defense agency, for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML. The contract has a firm fixed price, has no set-aside designation, and has a ceiling value of $32,264.46. The period of performance extends to June 13, 2025. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that holds a significant Indefinite Delivery Contract (IDC)...
- SPE2DB22D2218Indefinite Delivery Contract
- SPE2DB22D2218-SPE2DB24FR2GHDelivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HyperHEP B Vial 5 mL, a pharmaceutical product, with a ceiling value of $2,539.86 and a period of performance through April 23, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 that DLA awarded solely to Amerisourcebergen Drug Corp as the prime contractor. The IDC serves as the primary contract vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. No set-aside designation was used for this award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 4/2/24 |